Trial Watch: Immunotherapy plus radiation therapy for oncological indications

Erika Vacchelli, Norma Bloy, Fernando Aranda, Aitziber Buqué, Isabelle Cremer, Sandra Demaria, Alexander Eggermont, Silvia Chiara Formenti, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

66 Citaten (Scopus)

Samenvatting

Malignant cells succumbing to some forms of radiation therapy are particularly immunogenic and hence can initiate a therapeutically relevant adaptive immune response. This reflects the intrinsic antigenicity of malignant cells (which often synthesize a high number of potentially reactive neo-antigens) coupled with the ability of radiation therapy to boost the adjuvanticity of cell death as it stimulates the release of endogenous adjuvants from dying cells. Thus, radiation therapy has been intensively investigated for its capacity to improve the therapeutic profile of several anticancer immunotherapies, including (but not limited to) checkpoint blockers, anticancer vaccines, oncolytic viruses, Toll-like receptor (TLR) agonists, cytokines, and several small molecules with immunostimulatory effects. Here, we summarize recent preclinical and clinical advances in this field of investigation.

Originele taal-2Engels
Artikelnummere1214790
TijdschriftOncoImmunology
Volume5
Nummer van het tijdschrift9
DOI's
StatusGepubliceerd - 1 sep. 2016
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Trial Watch: Immunotherapy plus radiation therapy for oncological indications'. Samen vormen ze een unieke vingerafdruk.

Citeer dit